Abstract
Poorly biodegradable, incomplete Freund's adjuvant (IFA)-based anticancer vaccines primed CD8++ T cells that did not localize to the tumor site but to the persisting, antigen-rich vaccination site, which became a T-cell graveyard. Short-lived, water-based formulations and the provision of immunostimulatory molecules overcame this issue, resulting in tumor suppression. Here, we discuss the implications of these findings for the development of therapeutic anticancer vaccines.
Original language | English (US) |
---|---|
Article number | e24743 |
Journal | OncoImmunology |
Volume | 2 |
Issue number | 7 |
DOIs | |
State | Published - 2013 |
Keywords
- Antigen persistence
- Immunotherapy
- Sequestration
- T-cell deletion
- T-cell dysfunction
- T-cell trafficking
- Vaccine depot
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology